血管生成素1(ANGPT1)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法)
CLIA Kit for Angiopoietin 1 (ANGPT1)
ANG1; AGP1; AGPT; ANG-I
- 編號(hào)SCA008Hu
- 物種Homo sapiens (Human，人)相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)2h, 40min
- 檢測(cè)范圍0.55-400ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.21ng/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates and other biological fluids
- 下載英文說明書 中文說明書
- 規(guī)格48T96T96T*596T*1096T*100
- 價(jià)格¥ 3528¥ 5040¥ 22680¥ 42840¥ 352800
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
實(shí)驗(yàn)結(jié)果圖
標(biāo)準(zhǔn)曲線圖
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)血管生成素1(ANGPT1)，經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的血管生成素1(ANGPT1)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 79-90 | 83 |
| EDTA plasma(n=5) | 92-105 | 101 |
| heparin plasma(n=5) | 99-105 | 102 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的血管生成素1(ANGPT1)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中血管生成素1(ANGPT1)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 86-97% | 93-105% | 93-102% | 78-101% |
| EDTA plasma(n=5) | 86-98% | 84-91% | 84-103% | 83-90% |
| heparin plasma(n=5) | 93-101% | 90-99% | 83-99% | 97-105% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100μL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加底物100µL，37°C孵育10分鐘；
8. 讀數(shù)。
實(shí)驗(yàn)原理
將血管生成素1(ANGPT1)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的血管生成素1(ANGPT1)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的血管生成素1(ANGPT1)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入底物。加入底物后會(huì)產(chǎn)生輝光型光信號(hào)。發(fā)射光強(qiáng)度和樣品中的血管生成素1(ANGPT1)呈正相關(guān)。用化學(xué)發(fā)光儀測(cè)定相對(duì)光單位（RLU），計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA008Hu01 | 血管生成素1(ANGPT1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA008Hu02 | 血管生成素1(ANGPT1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA008Hu03 | 血管生成素1(ANGPT1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA008Hu01 | 血管生成素1(ANGPT1)多克隆抗體 | WB,IHC,ICC/IF |
| PAA008Hu02 | 血管生成素1(ANGPT1)多克隆抗體 | WB; IHC; ICC; IP. |
| FAA008Hu01 | 抗血管生成素1(ANGPT1)多克隆抗體 | Flow cytometry. |
| LAA008Hu71 | 血管生成素1(ANGPT1)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| MAA008Hu23 | 血管生成素1(ANGPT1)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA008Hu24 | 血管生成素1(ANGPT1)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA008Hu21 | 血管生成素1(ANGPT1)單克隆抗體 | WB |
| MAA008Hu22 | 血管生成素1(ANGPT1)單克隆抗體 | WB |
| FAA008Hu04 | 抗血管生成素1(ANGPT1)單克隆抗體 | Flow cytometry. |
| FAA008Hu02 | 抗血管生成素1(ANGPT1)單克隆抗體 | Flow cytometry. |
| FAA008Hu08 | 抗血管生成素1(ANGPT1)單克隆抗體 | Flow cytometry. |
| FAA008Hu06 | 抗血管生成素1(ANGPT1)單克隆抗體 | Flow cytometry. |
| LAA008Hu72 | 血管生成素1(ANGPT1)單克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| SEA008Hu | 血管生成素1(ANGPT1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| MEA008Hu | 血管生成素1(ANGPT1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCA008Hu | 血管生成素1(ANGPT1)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA008Hu | 血管生成素1(ANGPT1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Theriogenology | Evaluation of Changes in Doppler Ultrasonography Indices and Levels of Maternal Serum Angiogenic Factors throughout Pregnancy in Ewes[Science: Article] |
| J Atheroscler Thromb | High Mobility Group Box 1 Promotes Angiogenesis from Bone Marrow-derived Endothelial Progenitor Cells after Myocardial Infarction[PubMed: 25735431] |
| Archives of Biological Sciences | Diabetes-induced renal failure is associated with tissue inflammation and neutrophil gelatinase-associated lipocalin: Effects of resveratrol[publication:299492265_Diabetes-induced_renal_failu] |
| Am J Transl Res | Angiopoietin-1 facilitates recovery of hematopoiesis in radiated mice[Pubmed:27347310] |
| Clinical research | Increased plasma concentrations of interleukin 35 in patients with coronary artery disease[Journal:-19] |
| Turkish Journal of Medicl Sciences | A new angiogenesis prognostic index with VEGFA, PlGF, and angiopoietin 1 predicts survival in patients with advanced gastric cancer[pubmed:28425270] |
| Sci Rep.? | Flunarizine suppresses endothelial Angiopoietin-2 in a calcium - dependent fashion in sepsis.[pubmed:28276491] |
| PeerJ? | The ratio of serum Angiopoietin-1 to Angiopoietin-2 in patients with cervical cancer is a valuable diagnostic and prognostic biomarker[pubmed:28584715] |
| Molecular&cellular proteomics | Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry[pubmed:28550167] |
| Tumor Biology | Cervical cancer cell–derived angiopoietins promote tumor progression[pubmed:28720059] |
| Free Patents online | RHEUMATOID ARTHRITIS RELATED BIOMARKER[20170350884] |
| Anesthesiology | Vasculotide, an angiopoietin-1 mimetic, restores microcirculatory perfusion and microvascular leakage and decreases fluid resuscitation requirements in?…[Pubmed:28968277] |
| British Journal of Anaesthesia | Vasculotide, an angiopoietin-1 mimetic, reduces pulmonary vascular leakage and preserves microcirculatory perfusion during cardiopulmonary bypass in rats[10.1016:j.bja.2018.05.049] |
| The Journal of Biological Chemistry | Toll-like receptor 2 deficiency hyperactivates the FoxO1 transcription factor and induces aging-associated cardiac dysfunction in mice[Pubmed:29929978] |
| Clinical Significance of Nectin-4 Expression in Metastasis and Angiogenesis for Tumor Relapse[Doi: 10.4143/crt.2018.214] | |
| BIOLOGY?OF?REPRODUCTION | Prostaglandin-mediated effects in early canine corpus luteum: In vivo effects on vascular and immune factors[Pubmed: 30929911] |
| Scientific Reports | Association between Upper-airway Surgery and Ameliorative Risk Markers of endothelial function in obstructive Sleep Apnea[Pubmed: 31882827] |
| Biochem Biophys Res Commun | Effects of interleukin-6 and tumor necrosis factor-α on the expression of angiogenic and collagenolytic factors in premature and mature adipocytes[Pubmed: 32800538] |
| J Nutr Biochem | Effects of protein malnutrition on haematopoietic regulatory activity of bone marrow mesenchymal stem cells[33705953] |
| Intensive Care Med Exp | The effect of targeting Tie2 on hemorrhagic shock-induced renal perfusion disturbances in rats[33997943] |
| Gynecol Endocrinol | Potential of thrombospondin-1 in treatment of polycystic ovary syndrome rat model: a preliminary study[34282706] |
| Yonsei Med J | RAR-Related Orphan Receptor: An Accelerated Preeclampsia Progression by Activating the JAK/STAT3 Pathway[Pubmed:35619579] |